Baudax Bio Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Baudax Bio.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Baudax Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | 1 | -59 | -14 | -14 | N/A |
| 6/30/2023 | 1 | -61 | -16 | -16 | N/A |
| 3/31/2023 | 1 | -58 | -26 | -26 | N/A |
| 12/31/2022 | 1 | -59 | -28 | -28 | N/A |
| 9/30/2022 | 0 | 13 | -37 | -37 | N/A |
| 6/30/2022 | 1 | 0 | -45 | -45 | N/A |
| 3/31/2022 | 1 | -11 | -41 | -41 | N/A |
| 12/31/2021 | 1 | -20 | -49 | -49 | N/A |
| 9/30/2021 | 1 | -66 | -52 | -51 | N/A |
| 6/30/2021 | 1 | -38 | -51 | -50 | N/A |
| 3/31/2021 | 1 | -53 | -52 | -52 | N/A |
| 12/31/2020 | 0 | -76 | -45 | -44 | N/A |
| 9/30/2020 | 0 | -66 | -37 | -37 | N/A |
| 6/30/2020 | 0 | -88 | -28 | -29 | N/A |
| 3/31/2020 | N/A | -69 | -43 | -42 | N/A |
| 12/31/2019 | N/A | -33 | -52 | -50 | N/A |
| 9/30/2019 | N/A | -42 | -58 | -55 | N/A |
| 6/30/2019 | N/A | -51 | -71 | -68 | N/A |
| 3/31/2019 | N/A | -61 | -59 | -57 | N/A |
| 12/31/2018 | N/A | -74 | -63 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BXRX.Q's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if BXRX.Q's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if BXRX.Q's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BXRX.Q's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BXRX.Q's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BXRX.Q's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/04 03:43 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Baudax Bio, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Janney Montgomery Scott LLC |
| Jason Butler | JMP Securities |
| Gregory Aurand | NOBLE Capital Markets, Inc. |